



Robert Greene Sterne
 Edward J. Kessler
 Jorge A. Goldstein
 David K.S. Cornwell
 Robert W. Esmond
 Tracy-Gen G. Durkin
 Michele A. Cimbara
 Michael B. Ray
 Robert E. Sokohl
 Eric K. Steffe
 Michael Q. Lee
 Steven R. Ludwig
 John M. Covert
 Linda E. Alcorn
 Robert C. Millonig
 Lawrence B. Bugalsky
 Donald J. Featherstone
 Michael V. Messinger

Judith U. Kim
 Timothy J. Shea, Jr.
 Patrick E. Garrett
 Heidi L. Kraus
 Edward W. Yee
 Albert L. Fero*
 Donald R. Banowit
 Peter A. Jackman
 Molly A. McCall
 Teresa U. Medler
 Jeffrey S. Weaver
 Kendrick P. Patterson
 Vincent L. Capuano
 Eldora Ellison Floyd
 Thomas C. Fiala
 Brian J. Del Buono
 Virgil Lee Beaston*
 Kimberly N. Reddick

Theodore A. Wood
 Elizabeth J. Haanes
 Bruce E. Chalker
 Joseph S. Ostroff
 Frank R. Cottingham
 Christine M. Lhulier
 Rae Lynn Prengaman
 Jane Shereshenovich*
 Lawrence J. Carroll*
 George S. Bardmessner
 Daniel A. Klein*
 Rodney G. Maze
 Jason D. Eisenberg
 Michael D. Specht
 Andrea J. Kamage
 Tracy L. Muller
 Jon E. Wright*
 LuAnne M. Yuricek*

John J. Figueira
 Ann E. Summerfield
 Registered Patent Agents*
 Karen R. Markowicz
 Nancy J. Leith
 Helene C. Carlson
 Gaby L. Longsworth
 Matthew J. Dowd
 Aaron L. Schwartz
 Angelique G. Uy
 Mary B. Tung
 Katrina Y. Pei
 Bryan L. Skelton
 Robert A. Schwartzman
 Timothy A. Doyle
 Jennifer R. Mahalingappa

Teresa A. Colella
 Jeffrey S. Lundgren
 Victoria S. Rutherford
 Eric D. Hayes

Of Counsel
 Kenneth C. Bass III
 Evan R. Smith

*Admitted only in Maryland
 •Admitted only in Virginia
 •Practice Limited to
 Federal Agencies

41
 1652
 October 2, 2003

WRITER'S DIRECT NUMBER:
 (202) 772-8840

INTERNET ADDRESS:
 MTUNG@SKGF.COM

Art Unit 1652

Commissioner for Patents
 PO Box 1450
 Alexandria, VA 22313-1450

Re: U.S. Utility Patent Application
 Appl. No. 09/403,269; § 371 Date: October 18, 1999
 (U.S. National Phase of PCT/SE98/00703)

For: DNA Sequencing Encoding a Novel Glucuronyl C5-Epimerase (as RECEIVED
 amended)

Inventors: Lindahl *et al.*

Our Ref: 1708.0380000/MAC/MBT

OCT 06 2003

Sir:

TECH CENTER 1600/2900

Transmitted herewith for appropriate action are the following documents:

1. Amendment and Reply Under 37 C.F.R. § 1.111; and
2. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Mary B. Tung
 Mary B. Tung
 Agent for Applicants
 Registration No. 50,007

MAC/MBT/adw
 Enclosures

::ODMA\MHODMA\SKGF_DC1\183227;1

Sterne, Kessler, Goldstein & Fox PLLC : 1100 New York Avenue, NW : Washington, DC 20005 : 202.371.2600 f 202.371.2540 : www.skgf.com



THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

LINDAHL *et al.*

Application. No. 09/403,269

§ 371 Date: October 18, 1999

U.S. National Phase of PCT/SE98/00703

For: **DNA Sequence Encoding a Novel
Glucuronyl C5-Epimerase (as
amended)**

Confirmation No. 7046

Art Unit: 1652

Examiner: D. Steadman

Atty. Docket: 1708.0380000/MAC/MBT

Amendment and Reply Under 37 C.F.R. § 1.111 RECEIVED

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

OCT 06 2003

TECH CENTER 1600/2900

Sir:

In reply to the Office Action dated **July 10, 2003**, (PTO Prosecution File Wrapper Paper No. 28), applicants submit the following Amendment and Remarks. This Amendment is provided in the following format:

- (A) Each section begins on a separate sheet;
- (B) Starting on a separate sheet, amendments to the specification by presenting new paragraphs;
- (C) Starting on a separate sheet, a complete listing of all of the claims:
 - in ascending order;
 - with status identifiers; and
 - with markings in the currently amended claims;
- (D) Starting on a separate sheet, the Remarks.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.